SCHEMBL3588873

SCHEMBL3588873

CCOC(=O)Cc1c(Cl)ccc2cc(OS(=O)(=O)C(F)(F)F)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.39
PTGS2 P35354 1/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 2/20 0.36
POLB P06746 2/20 0.36
GAA P10253 1/20 0.36
KDM4E B2RXH2 2/20 0.35
LMNA P02545 2/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
MAPT P10636 3/20 0.35
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35
THRB P10828 1/20 0.35
CASP1 P29466 1/20 0.35
HTT P42858 1/20 0.35
CASP7 P55210 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
XBP1 P17861 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL991202 0.92 HSD11B1 (0.39) HSD11B1PTGS2KMT2AMEN1POLB
SCHEMBL3591326 0.83 PTGS2 (0.50) PTGS2GAAKDM4ELMNAMAPT
SCHEMBL149845 0.82 ALDH1A1 (0.38) HSD11B1KMT2AMEN1POLBGAA
SCHEMBL27665035 0.80 HSD11B1 (0.43) HSD11B1PTGDR2HTR1AHTR1DHTR1B
SCHEMBL27684654 0.79 HTR1D (0.38) HSD11B1HTR1AHTR1DHTR1BADORA1
SCHEMBL3586690 0.78 KDM4E (0.42) KMT2AMEN1GAAKDM4ELMNA
SCHEMBL3591481 0.76 KDM4E (0.40) PTGS2KMT2AMEN1POLBKDM4E
SCHEMBL4078469 0.74 GAA (0.45) HSD11B1KMT2AMEN1POLBGAA
SCHEMBL991313 0.74 PTGS2 (0.54) PTGS2GAAKDM4EMAPTHSD17B10
SCHEMBL151254 0.74 MAPT (0.40) KMT2AMEN1POLBKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691861-B2 Indolymaleimide derivatives NOVARTIS AG (CH) 2010-04-06 US disclosed
US-20080234494-A1 Indolylmaleimide Derivatives NOVARTIS AG (CH) 2008-09-25 US disclosed
EP-1709030-B1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2008-04-02 EP disclosed
EP-1709030-A1 INDOLYLMALEIMIDE DERIVATIVES Novartis AG (CH) 2006-10-11 EP disclosed
WO-2005068454-A1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234494-A1 Indolylmaleimide Derivatives IDH3A, INMT, IDH2 HSD11B1 1091/4885PTGS2 2126/4885KMT2A 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.